As of November 7, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Tango Therapeutics Inc. The largest reported stake is Fmr LLC's, at 15%. 35 filings are on record since July 17, 2025 (Schedule 13G/A, November 6, 2026).
Sell to companies like Tango Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 25,285,740 · Shared voting: 0 · Sole dispositive: 25,286,624 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-06
- · Reporting person: Farallon Capital Management, L.L.C. · Sole voting: 0 · Shared voting: 16,270,187 · Sole dispositive: 0 · Shared dispositive: 16,270,187 · SCHEDULE 13G/A, 2026-08-14
- · Holder: The Goldman Sachs Group, Inc. · Percent: 6% · SCHEDULE 13G
- · Holder: Woodline Partners LP · Percent: 2.5% · SCHEDULE 13G/A
- · Holder: TCG Crossover GP II, LLC · Percent: 7% · SCHEDULE 13G/A
Tango Therapeutics Inc has 35 Schedule 13D or 13G filings on record since 2025-07-17. 8 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 15% | 25,286,624 | SCHEDULE 13G/A, 2026-11-06 | 2026-10-30 |
| 9.99% | 13,461,215 | SCHEDULE 13G/A, 2026-02-06 | 2025-12-31 | |
| Farallon Capital Management, L.L.C. | 9.8% | 16,270,187 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| RTW Investments, LP | 9.3% | 13,300,620 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| 7.8% | 11,257,203 | SCHEDULE 13G/A, 2026-05-11 | 2026-03-31 | |
| TCG Crossover GP II, LLC | 7% | 10,147,867 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 6.3% | 8,477,165 | SCHEDULE 13G, 2026-01-21 | 2025-12-31 |
| The Goldman Sachs Group, Inc. | 6% | 9,742,403 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Third Rock Ventures IV, L.P. | 4.74% | 6,374,574 | SCHEDULE 13D/A, 2026-02-10 | 2026-02-06 |
| 4% | 5,657,105 | SCHEDULE 13G/A, 2026-05-04 | 2026-03-31 | |
| Adage Capital Management, L.P. | 3.44% | 5,600,000 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| Woodline Partners LP | 2.5% | 4,000,567 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
| EcoR1 Capital, LLC | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Nextech Crossover I GP S.a. r.l. | 0% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Tango Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Tango Therapeutics Inc and the records around it.
Tango Therapeutics Inc elsewhere on the record
- Leadership changes Aug 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- Third Rock Ventures IV, L.P. also filed stake reports on 1 other company: Maze Therapeutics, Inc. (Feb 2026)
- Nextech Crossover I GP S.a. r.l. also filed stake reports on 2 other companies: ORIC Pharmaceuticals, Inc. (Aug 2025)
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
Watch Tango Therapeutics Inc
Get an email when Tango Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tango Therapeutics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Tango Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tango Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
40 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 25,285,740 | 0 | 25,286,624 | 0 | SCHEDULE 13G/A, 2026-11-06 |
| Abigail P. Johnson | 0 | 0 | 25,286,624 | 0 | SCHEDULE 13G/A, 2026-11-06 |
| Farallon Capital Management, L.L.C. | 0 | 16,270,187 | 0 | 16,270,187 | SCHEDULE 13G/A, 2026-08-14 |
| Farallon Capital Partners, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Farallon Capital Institutional Partners, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Farallon Capital Institutional Partners II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Farallon Capital Institutional Partners III, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Four Crossings Institutional Partners V, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Farallon Capital Offshore Investors II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Farallon Capital (AM) Investors, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Farallon Capital F5 Master I, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Farallon Healthcare Partners Master, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Farallon Partners, L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Farallon Institutional (GP) V, L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Farallon F5 (GP), L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Farallon Healthcare Partners (GP), L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Dapice Joshua J. | 0 | 16,270,187 | 0 | 16,270,187 | SCHEDULE 13G/A, 2026-08-14 |
| Dreyfuss, Philip D. | 0 | 16,270,187 | 0 | 16,270,187 | SCHEDULE 13G/A, 2026-08-14 |
| Dunn Hannah E. | 0 | 16,270,187 | 0 | 16,270,187 | SCHEDULE 13G/A, 2026-08-14 |
| Gehani, Varun N. | 0 | 16,270,187 | 0 | 16,270,187 | SCHEDULE 13G/A, 2026-08-14 |
| Giauque, Nicolas | 0 | 16,270,187 | 0 | 16,270,187 | SCHEDULE 13G/A, 2026-08-14 |
| Husen, Avner A. | 0 | 16,270,187 | 0 | 16,270,187 | SCHEDULE 13G/A, 2026-08-14 |
| Kim, David T. | 0 | 16,270,187 | 0 | 16,270,187 | SCHEDULE 13G/A, 2026-08-14 |
| Linn, Michael G. | 0 | 16,270,187 | 0 | 16,270,187 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Tango Therapeutics Inc by CUSIP 87583X109 and gives its principal executive office as 201 BROOKLINE AVENUE, SUITE 901, BOSTON, MA 02215 (SCHEDULE 13G/A, 2026-11-06).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 5% | SCHEDULE 13G |
| 2025-08-12 | Adage Capital Management, L.P. | 5.45% | SCHEDULE 13G |
| 2025-08-13 | Dapice Joshua J. | 8.4% | SCHEDULE 13G/A |
| 2025-08-14 | Woodline Partners LP | 5.6% | SCHEDULE 13G |
| 2025-09-22 | Raymond Debbane | 5.3% | SCHEDULE 13G |
| 2025-11-12 | Dapice Joshua J. | 9.7% | SCHEDULE 13G/A |
| 2025-11-13 | Adage Capital Management, L.P. | 2.26% | SCHEDULE 13G/A |
| 2025-11-14 | Third Rock Ventures IV, L.P. | 6.97% | SCHEDULE 13D/A |
| 2025-11-14 | TCG Crossover GP II, LLC | 6.3% | SCHEDULE 13G/A |
| 2025-11-21 | Third Rock Ventures IV, L.P. | 5.85% | SCHEDULE 13D/A |
| 2026-01-21 | BlackRock, Inc. | 6.3% | SCHEDULE 13G |
| 2026-01-30 | The Vanguard Group | 5.01% | SCHEDULE 13G |
| 2026-02-06 | Dapice Joshua J. | 9.99% | SCHEDULE 13G/A |
| 2026-02-10 | Third Rock Ventures IV, L.P. | 4.74% | SCHEDULE 13D/A |
| 2026-02-12 | Adage Capital Management, L.P. | 7.88% | SCHEDULE 13G |
| 2026-02-13 | Raymond Debbane | 6.1% | SCHEDULE 13G/A |
| 2026-02-17 | Woodline Partners LP | 7.5% | SCHEDULE 13G/A |
| 2026-02-17 | EcoR1 Capital, LLC | 0% | SCHEDULE 13G/A |
| 2026-02-17 | TCG Crossover GP II, L.P. | 9.99% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-04 | Raymond Debbane | 4% | SCHEDULE 13G/A |
| 2026-05-06 | Fmr LLC | 6.9% | SCHEDULE 13G |
| 2026-05-11 | Dapice Joshua J. | 7.8% | SCHEDULE 13G/A |
| 2026-05-13 | Adage Capital Management, L.P. | 8.98% | SCHEDULE 13G/A |
| 2026-05-15 | Woodline Partners LP | 5.6% | SCHEDULE 13G/A |
| 2026-05-15 | TCG Crossover GP II, LLC | 8.1% | SCHEDULE 13G/A |
| 2026-05-15 | RTW Investments, LP | 9.3% | SCHEDULE 13G |
| 2026-05-15 | Nextech Crossover I GP S.a. r.l. | 5.1% | SCHEDULE 13G/A |
| 2026-08-12 | Adage Capital Management, L.P. | 3.44% | SCHEDULE 13G/A |
| 2026-08-14 | The Goldman Sachs Group, Inc. | 6% | SCHEDULE 13G |
| 2026-08-14 | Farallon Capital Management, L.L.C. | 9.8% | SCHEDULE 13G/A |
| 2026-08-14 | Woodline Partners LP | 2.5% | SCHEDULE 13G/A |
| 2026-08-14 | TCG Crossover GP II, LLC | 7% | SCHEDULE 13G/A |
| 2026-08-14 | Nextech Crossover I GP S.a. r.l. | 0% | SCHEDULE 13G/A |
| 2026-11-06 | Fmr LLC | 15% | SCHEDULE 13G/A |
Questions about who owns Tango Therapeutics Inc
Who owns Tango Therapeutics Inc?
On this page, 8 holders' latest ownership filings report 5% or more of Tango Therapeutics Inc: Fmr LLC (15%, Schedule 13G/A, filed 2026-11-06), Dapice Joshua J. (9.99%, Schedule 13G/A, filed 2026-02-06), Farallon Capital Management, L.L.C. (9.8%, Schedule 13G/A, filed 2026-08-14), RTW Investments, LP (9.3%, Schedule 13G, filed 2026-05-15) and Dapice Joshua J. (7.8%, Schedule 13G/A, filed 2026-05-11); 3 more are listed above.
Who are the largest shareholders of Tango Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Tango Therapeutics Inc on this page are Fmr LLC (15%), Dapice Joshua J. (9.99%) and Farallon Capital Management, L.L.C. (9.8%).
When did Fmr LLC buy into Tango Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-05-06, reporting 6.9%; its latest, Schedule 13G/A filed 2026-11-06, reports 15%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 35 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Tango Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 6, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| June 23, 2026 | Leadership change: Robert Azelby appointed, Director | — | Leadership changes | Source |
| May 13, 2026 | Leadership change: Alexis Borisy departs, Lead Independent Director, and 1 more | — | Leadership changes | Source |
| April 15, 2026 | Leadership change: Matthew Gall appointed, Chief Financial Officer, and 1 more | — | Leadership changes | Source |
| October 28, 2025 | Form D, private offering | $15M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Tango Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.